PERI-EDU University Education
A diagnosis label alone rarely determines implant suitability. Disease activity, oral manifestations, current treatment, healing capacity and the planned procedure define the clinical risk. Persistent or atypical peri-implant lesions require a wider differential diagnosis.
Risk begins with the current clinical state
Autoimmune disorders and cancer-related conditions are heterogeneous. The same diagnosis can describe a patient in stable remission, a person with active mucosal disease or someone receiving intensive systemic treatment. Implant planning should separate the underlying disease from treatment effects and from the local oral environment.
| Domain | Questions that matter | Implant relevance |
|---|---|---|
| Disease activity | Stable, fluctuating or active? Is organ function affected? | Active disease can alter healing, tolerance and the timing of elective care. |
| Oral expression | Xerostomia, ulceration, desquamation, fibrosis or fragile mucosa? | Oral manifestations can limit hygiene and complicate prosthesis design. |
| Medication | Glucocorticoid, immunosuppressant, biologic, antiresorptive, antiangiogenic or chemotherapy? | Drug class, dose, schedule and combined exposure can change infection, bone or mucosal risk. |
| Treatment phase | Induction, active chemotherapy, radiotherapy, maintenance or remission? | Timing may be more important than the historical diagnosis. |
| Local control | Periodontal stability, plaque control, infection and prosthetic access? | Uncontrolled local inflammation remains a direct and modifiable hazard. |
Autoimmune disease evidence
A 2025 scoping review identified 87 studies, dominated by case reports and retrospective designs. Reported implant survival ranged from 85.3% to 100%, but almost half or more of recorded losses in some disease groups occurred before loading. Implant therapy can be feasible while early healing deserves deliberate surveillance.
| Condition pattern | Relevant issue | Planning emphasis |
|---|---|---|
| Sjögren syndrome | Xerostomia can increase plaque retention, caries risk and mucosal discomfort. | Provide salivary care, hygiene access and a maintainable prosthesis. |
| Rheumatoid arthritis | Hand function, periodontal burden and immunomodulatory treatment vary widely. | Assess self-care capacity and medication context. |
| Oral lichen planus | Active erosive or ulcerative lesions can reduce tolerance and complicate diagnosis. | Aim for disease control before elective surgery and continue mucosal surveillance. |
| Fragile-mucosa disorders | Mechanical trauma can provoke painful erosions or interfere with cleaning. | Minimize traumatic contours and verify that maintenance is realistic. |
| Systemic lupus or scleroderma | Disease activity, organ involvement and immunosuppression can coexist. | Coordinate care when stability or treatment safety is uncertain. |
A retained implant can still have mucositis, peri-implantitis, pain or a prosthesis that the patient cannot maintain. Evidence remains too limited for reliable disease-specific risk percentages.
Immunosuppression and glucocorticoid exposure
Immune-modifying medicines affect different pathways. Their importance depends on indication, dose, duration, combination therapy and infection history. Implant studies often cannot separate medicine effects from the underlying disease.
- Chronic glucocorticoids: review dose, duration, infection history, glucose control, skeletal effects and possible adrenal suppression.
- Conventional immunosuppressants: medicine-specific leukopenia, organ toxicity and infection risk may justify current clinical or laboratory information.
- Biologic and targeted therapies: do not apply a universal interruption schedule.
- Combination treatment: reconcile the complete medicine list, including antiresorptive and oncologic treatment.
Stopping immunosuppressive, biologic or oncologic treatment can provoke disease flare or loss of cancer control. The prescribing team should decide whether timing adjustment is appropriate. A single universal neutrophil or platelet threshold does not fit every procedure and treatment protocol.
Cancer treatment changes timing and tissue reserve
A history of cancer does not create one permanent risk category. Current therapy, treatment field, marrow recovery, nutritional status and prognosis can alter the balance between functional rehabilitation and procedural burden.
| Clinical phase | Main issue | Implant implication |
|---|---|---|
| New diagnosis or staging | The oncologic plan may still be changing. | Defer elective implant surgery until treatment priorities are clear. |
| Cytotoxic chemotherapy | Neutropenia, thrombocytopenia and mucositis vary across the cycle. | Coordinate timing and use recent results when clinically indicated. |
| Targeted or immune therapy | Toxicities differ by agent. | Base decisions on the actual medicine and active adverse effects. |
| High-dose antiresorptive or antiangiogenic therapy | MRONJ risk can exceed that seen with osteoporosis regimens. | Use specialist planning before bone-invasive procedures. |
| Stable survivorship | Xerostomia, fibrosis or changed function can persist. | Plan for long-term tissue limitations and maintenance. |
Implant-supported rehabilitation can improve mastication, speech and retention when conventional prostheses cause trauma or perform poorly. The expected benefit should be weighed against surgical complexity and the likelihood of uninterrupted maintenance.
Head and neck radiotherapy
Radiotherapy can produce lifelong changes in bone vascularity, cellularity, salivary function and soft-tissue elasticity. Risk depends on the actual dose distribution to the proposed implant site, not simply on whether radiotherapy occurred.
- Obtain the radiotherapy summary and site-specific dose information when the proposed implant enters or approaches the treated field.
- Include time since treatment in the decision but do not use elapsed time as the only criterion.
- Assess xerostomia, mucosal fragility, fibrosis and hygiene capacity.
- Compare grafting with less invasive restorative alternatives.
- Use multidisciplinary assessment when dose information is uncertain or jaw exposure was substantial.
Osteoradionecrosis follows radiation injury. Medication-related osteonecrosis follows exposure to defined medicines in a patient without jaw radiation as the cause. The conditions can have overlapping risk factors but should not be used as interchangeable terms.
Persistent peri-implant disease can represent malignancy
Peri-implant oral malignancy can resemble inflammatory peri-implant disease. A 2025 systematic review and meta-analysis included 161 patients from 57 mostly low-level studies. About half of reported malignancies were initially diagnosed as peri-implantitis. Squamous cell carcinoma was the predominant final diagnosis.
| Finding | Possible inflammatory explanation | Reason to widen the differential |
|---|---|---|
| Bleeding or suppuration | Mucositis or peri-implantitis. | Induration, ulceration or tissue proliferation. |
| Marginal bone loss | Biofilm-associated peri-implantitis. | Rapid, irregular or unexpectedly extensive destruction. |
| Hyperplastic tissue | Inflammatory granulation tissue. | Exophytic growth, firmness, altered color or recurrence. |
| Pain or paraesthesia | Infection or a mechanical complication. | Neurosensory change or unexplained progression. |
| Non-response | Residual biofilm or difficult access. | Failure after correctly delivered and reviewed care. |
Reported cases occurred without smoking, alcohol exposure or a previous cancer diagnosis. Persistent ulceration, proliferative tissue, rapid progression or failure to respond to treatment should prompt timely referral and histopathological diagnosis.
Transplantation and combined systemic risk
Solid-organ transplant recipients combine lifelong immunosuppression with graft function, polypharmacy and possible metabolic or skeletal disease. Reviews report favorable implant survival in selected recipients, but the evidence remains small and protocol-specific.
- Confirm stable graft function and absence of recent rejection or intensified immunosuppression.
- Adapt analgesia, antimicrobial use and surgical burden to renal or hepatic function.
- Add MRONJ assessment when glucocorticoid-related osteoporosis leads to antiresorptive treatment.
- Stabilize periodontitis, candidiasis, xerostomia and other local disease.
- Do not use routine antibiotics as a substitute for careful patient selection and infection control.
A focused preoperative pathway
- Define the benefit: document functional limitations, alternatives and expected improvement.
- Establish current disease status: record activity, organ involvement, oral manifestations and recent complications.
- Reconcile treatment: record medicine, indication, dose, schedule, duration and recent changes.
- Assess local readiness: control infection and evaluate anatomy, mucosa, hygiene and prosthetic access.
- Match procedural burden: select the least burdensome plan that meets the restorative need.
- Build surveillance: define healing reviews, maintenance and a red-flag referral pathway.
Clinical synthesis
- Judge current disease activity and treatment exposure rather than the diagnosis label alone.
- Control active mucosal disease before elective implant surgery.
- Watch early healing closely in patients with autoimmune disease.
- Do not independently stop immunosuppressive or oncologic treatment.
- Coordinate implant timing with the actual oncology treatment phase.
- Obtain site-specific radiotherapy information when the jaw may have entered the field.
- Distinguish osteoradionecrosis from MRONJ.
- Refer atypical or non-responsive peri-implant lesions for biopsy.
Download the full educational material
The full PDF expands the evidence, disease-specific considerations, medicine review, oncology timing, radiotherapy assessment, malignant differential diagnosis and a structured preoperative pathway.
Download the full educational material (PDF)
Selected references
- Hyldahl E, et al. Dental Implant Therapy in Patients With Autoimmune Diseases: A Scoping Review. Clin Oral Implants Res. 2025.
- Stavropoulos A, et al. Survival and Success of Dental Implants in Patients with Autoimmune Diseases: a Systematic Review. 2024.
- Duttenhoefer F, et al. Dental implants in immunocompromised patients: systematic review and meta-analysis. Int J Implant Dent. 2019;5:43.
- Burtscher D, et al. Dental implant procedures in immunosuppressed organ transplant patients: a systematic review. Int J Oral Maxillofac Surg. 2022.
- Peterson DE, et al. Prevention and Management of Osteoradionecrosis: ISOO-MASCC-ASCO Guideline. J Clin Oncol. 2024.
- Srinivasan M, et al. Peri-implantitis and peri-implant oral malignancies: a systematic review and meta-analysis. J Dent. 2025;160:105897.
Explore related PERI-EDU resources
#UniversityEducation #OnlineCourses #ClinicalCases #PERIEDU #AutoimmuneDisease #CancerCare #DentalImplants #OralMedicine
This material supports structured implant risk assessment and interdisciplinary communication. It does not replace oncology, rheumatology, transplant, oral medicine or maxillofacial specialist care.
This work was co-funded by the European Union under grant agreement No. 2024-1-PL01-KA220-HED-000251208. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the Foundation for the Development of the Education System (FRSE). Neither the European Union nor FRSE can be held responsible for them.